JP2025511187A5 - - Google Patents

Info

Publication number
JP2025511187A5
JP2025511187A5 JP2024558023A JP2024558023A JP2025511187A5 JP 2025511187 A5 JP2025511187 A5 JP 2025511187A5 JP 2024558023 A JP2024558023 A JP 2024558023A JP 2024558023 A JP2024558023 A JP 2024558023A JP 2025511187 A5 JP2025511187 A5 JP 2025511187A5
Authority
JP
Japan
Prior art keywords
seq
target
binding protein
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/017130 external-priority patent/WO2023192606A2/en
Publication of JP2025511187A publication Critical patent/JP2025511187A/ja
Priority to JP2026057622A priority Critical patent/JP2026099821A/ja
Publication of JP2025511187A5 publication Critical patent/JP2025511187A5/ja
Pending legal-status Critical Current

Links

JP2024558023A 2022-04-01 2023-03-31 Cd3結合タンパク質及びその使用方法 Pending JP2025511187A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026057622A JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326668P 2022-04-01 2022-04-01
US63/326,668 2022-04-01
PCT/US2023/017130 WO2023192606A2 (en) 2022-04-01 2023-03-31 Cd3-binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026057622A Division JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Publications (2)

Publication Number Publication Date
JP2025511187A JP2025511187A (ja) 2025-04-15
JP2025511187A5 true JP2025511187A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=86185147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024558023A Pending JP2025511187A (ja) 2022-04-01 2023-03-31 Cd3結合タンパク質及びその使用方法
JP2026057622A Pending JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026057622A Pending JP2026099821A (ja) 2022-04-01 2026-03-31 Cd3結合タンパク質及びその使用方法

Country Status (5)

Country Link
US (1) US20250230239A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504782A2 (cg-RX-API-DMAC7.html)
JP (2) JP2025511187A (cg-RX-API-DMAC7.html)
CN (1) CN119278215A (cg-RX-API-DMAC7.html)
WO (1) WO2023192606A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス,インコーポレイテッド 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
CN111212853A (zh) 2017-08-30 2020-05-29 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20200405890A1 (en) 2018-02-21 2020-12-31 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
KR20200142525A (ko) * 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
BR112021008526A2 (pt) 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
WO2020236679A1 (en) 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
US20220306745A1 (en) 2019-06-13 2022-09-29 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
WO2020252358A1 (en) 2019-06-13 2020-12-17 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
EP4034171A1 (en) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥(上海)有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
AU2021206218A1 (en) 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2021087429A5 (cg-RX-API-DMAC7.html)
JP2023526428A5 (cg-RX-API-DMAC7.html)
JP5011277B2 (ja) ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
JP2019513014A5 (cg-RX-API-DMAC7.html)
US9540618B2 (en) Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN103242451B (zh) 基于免疫球蛋白的多价生物活性装配体
Lu et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment
JP2009517337A (ja) 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
JP7832926B2 (ja) 制約され、条件付きで活性化された結合タンパク質
CN104321081A (zh) 免疫治疗分子和用途
JP7855148B2 (ja) 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
SG10202110908WA (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
JP2025511713A5 (cg-RX-API-DMAC7.html)
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2024531338A5 (cg-RX-API-DMAC7.html)
JP2025511190A5 (cg-RX-API-DMAC7.html)
RU2020123264A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
US20170121692A1 (en) Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses
CN121752768A (zh) 经遮蔽抗体、文库及其使用方法
WO2026024863A2 (en) Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
KR20260057503A (ko) 고효율, 조건부-활성화된 항체 발굴 및 마스킹된 항체
HK1135901A (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses